| Shangqin Liu,Chengsi Gui. Megakaryocyte aplastic thrombocytopenia after CAR T-cell therapy in a patient with multiple myeloma: A case report. Oncol Transl Med, 2021, 7: 45-47. |
| 双靶向CAR T细胞治疗难治性多发性骨髓瘤后出现巨核细胞再障：病例报告 |
| Megakaryocyte aplastic thrombocytopenia after CAR T-cell therapy in a patient with multiple myeloma: A case report |
| Received:August 09, 2020 Revised:February 22, 2021 |
| DOI：10.1007/s10330-020-0450-0 |
| 中文关键词: CAR T 细胞治疗；难治性多发性骨髓瘤；巨核细胞再障性血小板减少；病例报告 |
| 英文关键词: megakaryocyte aplastic thrombocytopenia; chimeric antigen receptor (CAR) T cell therapy; multiple myeloma; case report |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Shangqin Liu* | Department of Hematology, Zhongnan Hospital of Wuhan University | ubeliu@aliyun.com | | Chengsi Gui | Department of Hematology, Zhongnan Hospital of Wuhan University | |
|
| Hits: 9761 |
| Download times: 11988 |
| 中文摘要: |
| 嵌合抗原受体(CAR)T细胞治疗是一种有效的血液恶性肿瘤的新治疗方法。 白血病和淋巴瘤CART细胞治疗的成功促进了多发性骨髓瘤(MM)CART细胞治疗的发展，初步结果令人鼓舞。 在MM中已被临床评价的CART细胞治疗靶抗原包括CD19、B细胞成熟抗原(BCMA)、CD38、CD138等。广泛使用CART细胞治疗的障碍是毒性，主要是细胞因子释放综合征(CRS)、神经毒性。 本文介绍了一例难治性MM患者在双靶向CAR T细胞治疗后出现巨核细胞再生性血小板减少症，关于此种副作用尚未报告过。目前予以输注血小板等对症支持治疗，患者目前病情平稳，院外定期随诊。现CAR T细胞治疗的相关研究正在进行中，其各种副作用会不断出现，如何治疗副作用、改善患者预后是一个巨大的挑战。 |
| 英文摘要: |
| Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment strategy for hematologic
malignancies. The success of CAR T-cell therapy in treating leukemia and lymphoma has promoted
its development for multiple myeloma (MM), and the initial results of CAR T cell therapy have been
encouraging. CAR T-cell therapy target antigens that have been clinically evaluated in MM; these antigens
include CD19, B cell maturation antigen (BCMA), CD38, and CD138. A barrier to the widespread use of
CAR T-cell therapy is its toxicity, primarily cytokine release syndrome (CRS), and neurologic toxicity. This
study reports a patient with refractory MM who also developed megakaryocyte aplastic thrombocytopenia
after receiving CAR T-cell therapy; such a case or the unusual side effects involving medications are yet
unreported. There are risks in using cyclosporine and other immunosuppressants that may lead to MM
recurrence as the use of such substances is contradictory to previous treatments; therefore, we temporarily
administered platelet infusion as supportive care. Thus far, the condition of the patient has been steady and
the patient regularly takes blood test in the hospital. |
|
View Full Text
Download reader HTML全文 |
| Close |